Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol

R. Sydes, Matthew; Spears, Melissa; D. Mason, Malcolm; W. Clarke, Noel; P. Dearnaley, David; S. de Bono, Johann; Attard, Gerhardt; Chowdhury, S.; Cross, William; Gillessen, Silke; Malik, Zafar; J. Jones, Robert; Parker, Chris; Ritchie, A.W.S.; M. Russell, John; Millman, R.; Matheson, David; Amos, Claire; Gilson, Clare; Birtle, Alison; Brock, Susannah; Capaldi, Lisa; Chakraborti, P.; Choudhury, Ananya; Evans, Linda; Ford, Daniel; Gale, Joanna; Gibbs, Stephanie; C. Gilbert, Duncan; Hughes, Robert; B. McLaren, Duncan; Lester, J.F.; Nikapota, Ashok; M. O’Sullivan, Joe; Parikh, Omi; Peedell, C.; Protheroe, Andrew; Maria Rudman, Sarah; Shaffer, Richard; Sheehan, Denise; Simms, Matthew; Srihari, Narayanan; T. Strebel, Raeto; Sundar, Santhanam; Tolan, Shaun; Tsang, D.; Varughese, M.; Wagstaff, John; Parmar, Mahesh; D. James, Nicholas

doi:10.1093/annonc/mdy072

Public

Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol

Published in Annals of Oncology • Feb 20, 2018

Authors:

Matthew R. Sydes

Melissa Spears

Malcolm D. Mason

Abstract

Background: Adding abiraterone acetate with prednisolone (AAP) or docetaxel with prednisolone (DocP) to standard-of-care (SOC) each improved survival in systemic therapy for advanced or metastatic prostate cancer: evaluation of drug efficacy: a multi-arm multi-stage platform randomised controlled pr...

Subject

Medicine

Docetaxel

Prostate cancer

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!